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ABSTRACT
Background
Schistosomiasis—infection with helminth parasites in the genus Schistosoma, including S.
mansoni—is a widespread, devastating tropical disease affecting more than 200 million people.
No vaccine is available, and praziquantel, the only drug extensively utilized, is currently
administered more than 100 million people yearly. Because praziquantel resistance may
develop it is essential to identify novel drug targets. Our goal was to investigate the potential
of a unique, selenium-containing parasite enzyme thioredoxin glutathione reductase (TGR) as a
drug target.
Methods and Findings
Using RNA interference we found that TGR is essential for parasite survival; after silencing of
TGR expression, in vitro parasites died within 4 d. We also found that auranofin is an efficient
inhibitor of pure TGR (Ki ¼ 10 nM), able to kill parasites rapidly in culture at physiological
concentrations (5 lM), and able to partially cure infected mice (worm burden reductions of
;60%). Furthermore, two previously used antischistosomal compounds inhibited TGR activity,
suggesting that TGR is a key target during therapy with those compounds.
Conclusions
Collectively, our results indicate that parasite TGR meets all the major criteria to be a key
target for antischistosomal chemotherapy. To our knowledge this is the first validation of a
Schistosoma drug target using a convergence of both genetic and biochemical approaches.
The Editors’ Summary of this article follows the references.
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Schistosomiasis (also known as bilharzia)—infection with
the helminth parasites in the genus Schistosoma—remains an
important infection in many tropical areas, especially Africa.
More than 200 million people have schistosomiasis, with 20
million exhibiting severe symptoms. Recent analyses suggest
that the morbidity due to schistosomiasis is grossly under-
estimated [1], resulting in an estimated 280,000 deaths
annually in sub-Saharan Africa alone [2]. Since the mid-
1980s praziquantel (Figure S1) has been the drug of choice for
schistosomiasis; effectively it is currently the only choice
available. Artemether has shown promise as a new drug for
schistosomiasis, targeting larval parasites more effectively
than praziquantel, which is primarily effective against adult
parasites [3]. However, the use of artemether for schistoso-
miasis should be restricted so that its use as an antimalarial
compound is not put at risk from the development of possible
drug resistance in the malaria parasite. With the exception of
the artemisinin-based drugs, no new drugs have been
introduced for schistosomiasis after praziquantel, and prior
drugs have ceased to be produced or are ineffective [4].
Furthermore, resistance to oxamniquine, which is effective
against S. mansoni, has been reported [5], thereby reducing its
potential usefulness. Research for new antischistosome drugs
is limited by the difﬁculty of working with the parasite and
the low priority the pharmaceutical industry generally places
on tropical diseases. Currently more than 100 million people
are being treated for schistosomiasis with praziquantel [2];
they are rapidly reinfected and must be retreated on an
annual or semiannual basis. If praziquantel-resistant parasites
develop, treatment for schistosomiasis will be in a crisis state.
Adult S. mansoni parasites reside in the mesenteric veins of
their human hosts, where they can survive for up to 30 years
[6]. Living in an aerobic environment, worms must have
effective mechanisms to maintain cellular redox balance.
Additionally, worms must be able to evade reactive oxygen
species generated by the host’s immune response. In most
eukaryotes there are two major systems to detoxify reactive
oxygen species, one based on the tripeptide glutathione
(GSH) and the other based on the 12 kDa protein thioredoxin
(Trx). In both systems reducing equivalents are provided by
NADPH via dedicated oxidoreductase ﬂavoenzymes. Gluta-
thione reductase (GR) reduces glutathione disulﬁde (GSSG)
and drives the GSH-dependent systems [7,8], whereas Trx
reductases (TrxR) are pivotal in the Trx-dependent system
(Figure 1) [9]. In addition to providing protection against
oxidative damage, the Trx and GSH systems also play
important roles in cell proliferation, redox regulation of
gene expression, xenobiotic metabolism, and several other
metabolic functions [8,9]. Because of the diverse functions of
the TrxR- and GR-dependent pathways, the two oxidoreduc-
tases have been identiﬁed as promising targets for drug
development for many diseases, including malaria, trypano-
somiasis, and cancer [9,10].
It was recently discovered that in S. mansoni, specialized
TrxR and GR enzymes are absent, and instead replaced by a
unique multifunctional enzyme, thioredoxin glutathione
reductase (TGR) (Figure 1) [11]. This reliance on a single
enzyme for both GSSG and Trx reduction suggests that the
parasite’s redox systems are subject to a bottleneck depend-
ence on TGR. The amino acid sequence and domain structure
of schistosome TGR has similarities to mammalian forms of
TrxR and GR, with an additional amino-terminal extension of
a glutaredoxin (Grx) domain of ;110 amino acids with a
typical CPYC active site [11]. Like all mammalian TrxR
isoforms, S. mansoni TGR is a selenoprotein with a carboxyl-
terminal GCUG active site motif, where ‘‘U’’ is selenocysteine
(Sec). Sec is a highly reactive amino acid that gives unique
properties to selenoproteins [12]. It is encoded by a dedicated
UGA codon in the selenoprotein mRNA and is recoded from
translational termination to Sec insertion by a translation
machinery utilizing a specialized structural element in the 39-
untranslated region, the SECIS element, which is also found
in the mRNA of S. mansoni TGR [11].
Given the importance of cellular redox systems and the
biochemical differences between the redox metabolism of S.
mansoni and its human host, we hypothesized that TGR could
be an essential parasite protein and a potentially important
drug target. To test this hypothesis, we used RNA interfer-
ence (RNAi), characterized the recombinant selenoprotein,
and screened inhibitory compounds, including two estab-
lished antischistosomal drugs that are no longer commonly
used, potassium antimonyl tartrate (PAT) and oltipraz (OPZ).
Methods
Parasite Preparation
Percutaneous infection of outbred mice (NIH Swiss or
Swiss-Webster) with S. mansoni cercariae (NMRI strain)
obtained from infected Biomphalaria glabrata snails, perfusion
of adult worms (6–7 wk) and juvenile worms (23 d) and
preparation of schistosomula from cercariae were as de-
scribed [13]. This study was approved by the Institutional
Figure 1. Redox Pathways in Mammals and S. mansoni
In mammals (upper pathway), electrons from NADPH are transferred to
an oxidoreductase flavoenzyme, either thioredoxin reductase (TrxR) or
glutathione reductase (GR). Electrons are then transferred from the
oxidoreductase flavoenzyme to the appropriate electron carrier, either
oxidized thioredoxin (Trx-S2) or glutathione disulfide (GSSG) converting
them to reduced thioredoxin (Trx-[SH]2) or glutathione (GSH), respec-
tively. Trx-(SH)2 and GSH then supply reducing equivalents for a number
of different reactions, including those that are glutaredoxin (Grx)-
dependent. In S. mansoni (lower pathway), TrxR and GR are replaced with
a unique oxidoreductase flavoenzyme, TGR, which provides reducing
equivalents for Trx-, GSH- and Grx-dependent reactions.
doi:10.1371/journal.pmed.0040206.g001
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(08–2002; Department of Health and Human Services animal
welfare assurance number A3762–01).
Recombinant Sec TGR Expression and Purification
A bacterial-type SECIS element was fused to the TGR open
reading frame [14] using PCR with the following oligonucleo-
tides primers: forward 59-catATGCCTCCAGCTGATGGAAC-
39 and reverse 59-TCGCCAACGACTCCAATTATTAGC-
CAACGTCCAGACGTGGTTAGCAATTGGATACGCGGG-
cagctg-39. The entire TGR ORF plus the SECIS element was
subcloned into pET-24a using NdeI/SalI to release the insert.
Recombinant TGR was subsequently expressed in the
Escherichia coli strain BL21(DE3) in the presence of pSUABC
[14] in LB medium supplemented with 20 lM ﬂavin adenine
dinucleotide, and otherwise conditions for optimal seleno-
protein expression were followed as described [15]. Cultures
were centrifuged, lysed by alternative freeze-thaw, resus-
pended in TE buffer and supplemented with 20 lM ﬂavin
adenine dinucleotide. The sample was sonicated and cellular
debris pelleted at 25,000g at 4 8C for 25 min. The supernatant
was collected and ﬁltered through a 0.45 lm ﬁlter and
brought to a ﬁnal concentration of 200 mM NaCl. TGR was
then puriﬁed on an adenosine 29,59-diphosphate agarose
(Sigma, http://www.sigma-aldrich.com) column equilibrated
with TE buffer. The column was washed with 50 ml of TE.
TGR was eluted with 1 mM NADPH in TE essentially as
described [14,15]. The TGR sample (1/50 volume cell culture)
was applied to a 2.5 ml column, which was then washed with
50 ml of TE after which TGR was eluted in ten 1 ml fractions
of 1 mM NADPH in TE. Protein purity was .95% as
determined by SDS-PAGE, and TGR concentration was
determined from the ﬂavin adenine dinucleotide absorption
(e463¼11.3 mM
 1cm
 1). The pure protein was dialyzed against
PBS and stored at  80 8C. Overall yield was ;10 mg of
puriﬁed protein per liter of culture.
TGR Enzymatic Assays
Assays were performed at 25 8C in 0.1 M potassium
phosphate (pH 7.4), 10 mM EDTA using 100 lM NADPH
unless otherwise stated. The insulin assay and the 5,59-
dithiobis(2-nitrobenzoic acid) (DTNB) assays were used to
determine the TrxR activity of TGR. The DTNB assay [16]
contained 3 mM DTNB, and the initial increase in A412
during the ﬁrst 3 min was recorded upon enzyme addition.
One enzyme unit in the DTNB reduction assay was deﬁned as
the NADPH-dependent production of 2 lmol of 2-nitro-5-
thiobenzoic acid per minute using e412 nm ¼ 13.6 mM
 1 cm
 1.
The insulin assay [17] mixture contained 1 mg/ml insulin and
10 lM schistosome Trx1 [18], and enzyme activity was
monitored by observing the decrease in A340 during the ﬁrst
3 min due to consumption of NADPH (e340 nm ¼ 6.22 mM
 1
cm
 1). GR activity was determined with 100 lM GSSG [19].
Grx activity was determined by monitoring the consumption
of NADPH at 340 nm during the GSH-dependent reduction
of 8 mM b-hydroxyethyl disulﬁde (HED) using 1 mM GSH
coupled with of 0.6 units of yeast GR (Sigma) [20].
The inhibitory action of both PAT and OPZ was addressed
by varying substrate and inhibitor concentrations as follows:
DTNB 50, 100, 400, 1000 lM; GSSG 10, 25, 50, 100 lM; PAT
10, 30, 75 nM; OPZ 25, 50, 100 lM. The inhibitory constants
(Ki) were determined using Equation 1 [21]:
1=vmaxapp ¼ð 1 þ½ I =KiÞ=vmax; ð1Þ
where vmaxapp is the apparent vmax at different inhibitor
concentrations and corresponds to the value of the 1/v
intercept on the reciprocal plot.
Initial inhibitor screens were conducted in 200 ll volumes
in 96 well plates with 50 lM inhibitor, 100 lM NADPH, and 5
nM TGR in 0.1 M potassium phosphate (pH 7.4), 10 mM
EDTA with a preincubation step of 15 min. Aurothioglucose
was obtained from Research Diagnostics (http://www.
researchd.com); aurothiomalate, menadione, methylene blue,
naphthazarin, plumbagin, praziquantel, PAT, and safranin
were from Sigma; OPZ was a gift from Dr. D. Cioli; auranoﬁn
(AF) was a gift from Dr. C.F. Shaw; and all other compounds
were prepared as described in the references in the
appropriate Tables. Upon addition of another aliquot of
NADPH (ﬁnal NADPH concentration of 100–200 lM) and 3
mM DTNB the activity was measured during the ﬁrst 3 min by
monitoring the A412. Residual activity was compared to
controls incubated with equal volumes of inhibitor solvent.
Compounds exhibiting .85% inhibition were analyzed in
detail to determine IC50 values using the assays described
above and including a 15 min preincubation step of TGR plus
inhibitor and 100 lM NADPH. All assays were done in
triplicate.
Kinetic Analysis
TGR activity with the following substrates was determined:
GSSG, GSH, HED, S. mansoni Trx1 [18], DTNB, H2O2, t-butyl
hydroperoxide, L-cysteine, sodium selenite, lipoic acid, lip-
oamide, alloxan, dehydroascorbic acid, and ubiquinone by
monitoring the oxidation of NADPH. In all assays the
reactions were performed in 1 ml 0.1 M potassium phosphate
(pH 7.4), 10 mM EDTA using 100 lM NADPH and 20 nM
TGR. Kinetic parameters were determined using Lineweaver–
Burk plots using KaleidaGraph 4 (Synergy Software, http://
www.synergy.com) least squares best ﬁt of data and varying
concentrations of one substrate while maintaining the
concentration of other substrates. In the TrxR assays,
substrate concentrations ranged from 2.5 to 200 lM NADPH
and from 0.25 to 15 lM S. mansoni Trx1 or from 100 to 4,000
lM DTNB. To determine kinetic parameters for GR activity
of TGR, substrate concentrations varied from 7.5 to 100 lM
GSSG and from 10 to 100 lM NADPH. Grx activity was
determined by using 25 to 4,000 lM HED, 10 to 100 lM GSH,
and 1 to 100 lM NADPH. All assays were done in triplicate.
Inhibitor Studies on Cultured Worms
AF was dissolved in DMSO and added to freshly perfused
worms in DMEM to 10 lM. Control worms were treated with
equal amounts of carrier. Worms were subsequently observed
for unpairing, motility, and mortality, and were collected at
the indicated time intervals for analysis. Worms were
homogenized by sonication in PBS and homogenates were
assayed for TrxR and GR activities as described above.
Activities of the control enzymes GSH peroxidase (GPx) and
lactate dehydrogenase (LDH) were determined using pub-
lished methods [22,23] with 1 mM sodium azide, 3.0 units of
yeast GR (Sigma), 1 mM GSH, 0.02 mM DTT, 0.0007% (w/v)
H2O2, and 100 lM NADPH in the GPx assay and 10 lM
sodium pyruvate and 100 lM NADPH in the LDH assay. A
replicate experiment was performed in which the worms were
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was determined as described [24]. Each assay was done in
triplicate and each experiment was done three times.
Inhibitor Studies on Infected Mice
Mice (14-wk-old females; C57BL/6 in experiment 1, NIH-
Swiss in experiment 2) infected with 60 S. mansoni cercariae
were injected intraperitoneally with 6 mg/kg of AF twice daily
for 9 d, beginning 7 wk post infection. Infected control mice
were injected with equal amounts of carrier. Mice were
perfused 1 wk after the ﬁnal dose of AF and worm burdens
were determined.
RNA Silencing
A 500-nucleotide fragment (bp 1364–1866) of S. mansoni
TGR was ampliﬁed by PCR (forward primer 59-CTATTTGGC
TAGACGTCTGT-39 and reverse primer 59-AATA
CAGTTTCCTTCCCGTT-39) and cloned into PCRII-TOPO
vector (Invitrogen, http://www.invitrogen.com). The resulting
construct was linearized using XhoI (for SP6 RNA polymerase
transcription) and SacI (for T7 RNA polymerase transcrip-
tion). RNA transcription was conducted according to
manufacturer’s instructions (Ambion, http://www.ambion.
com). A 280-bp, nonschistosome dsRNA used for irrelevant
dsRNA negative controls was synthesized from the PCRII-
TOPO vector using T7 or SP6 RNA polymerases as described
above.
Cercariae were mechanically transformed to schistosomula
by vortexing, and bodies were separated from tails by Percoll
gradient centrifugation as described [13]. Immediately after
transformation, TGR dsRNA or irrelevant dsRNA (each at 54
lg/ml) was added to ;500 schistosomula in 50 ll water
followed by incubation at 37 8C for 30 min. After addition of
250 ll of RPMI-1640 medium, 300 U/ml penicillin, and 175 lg/
ml streptomycin, parasites were incubated at 37 8Ci n5 %
CO2 atmosphere for 4 d. Reduced O2 tension was obtained by
ﬁltering media and purging with 95% N2,5 %C O 2 for 20 min
before use. Parasites were cultured during the course of the
Table 1. Kinetics of Recombinant S. mansoni TGR with Different Substrates
Substrate Km, lMV max, lM min
 1 kcat,s
 1 kcat/Km,M
 1 s
 1
NADPH 13.7 6 2.4 25.1 6 1.8 20.1 1.5 3 10
6
SmTrx1 6.37 6 0.9 36 6 1.7 30 4.7 3 10
6
DTNB 114 6 9.0 19.2 6 1.6 16 1.4 3 10
5
GSSG 71.5 6 11.8 26 6 3.5 21.7 3.0 3 10
5
HED 1,867 6 92 21.4 6 0.33 17.8 9.6 3 10
3
GSH 248.6 6 7.8 24.1 6 3.9 20.1 8.1 3 10
4
Na2SeO3 66.7 6 6.9 2.54 6 0.046 2.1 3.1 3 10
4
H2O2 68,000 6 5,000 11.3 6 0.46 9.4 1.4 3 10
2
t-Butyl-OOH 48,550 6 2,000 12.8 6 0.33 10.7 2.2 3 10
2
Alloxan 1,140 6 220 29.5 6 4.5 24.6 2.2 3 10
4
Lipoic acid 2,610 6 300 2.03 6 0.135 1.7 6.5 3 10
2
Lipoamide 1,342 6 11.4 14.2 6 0.46 11.8 8.8 3 10
3
DHAA NA ,0.3 ,0.25 NA
Ubiquinone NA ,0.3 ,0.25 NA
Kinetic constants for recombinant Schistosoma mansoni TGR (20 nM) were determined in assays performed at 25 8C in 0.1 M potassium phosphate (pH 7.4), 10 mM EDTA using 100 lM
NADPH. The standard deviations from three independent experiments are shown.
DHAA, dehydroascorbic acid; NA, not applicable; t-butyl-OOH, tert-butyl hydroperoxide.
doi:10.1371/journal.pmed.0040206.t001
Table 2. Comparison of the Kinetic Properties of Human TrxR1, TGR, and GR to Recombinant S. mansoni TGR
Property Substrate Human TrxR1 [26] Human TGR [26] Human GR S. mansoni TGR
Specific activity, lmol min
 1mg
 1 NADPH þ DTNB 25 3.1 ND 10.2
NADPH þ Trx 5.9 4.2 ND 2.2
NADPH þ GSSG ND 2.0 240 [27] 7.2
NADPH þ HED ND 1.9 ND 9.9
Apparent Km, lM DTNB 212 14.7 — 114
NADPH 19.6 10.7 8.5 [28] 13.7
Trx 4.73 3.0 — 6.37
GSSG — 8.84 65 [28] 71.5
HED — 45.2 — 1,867
Apparent kcat,s
 1 DTNB 86 6.5 — 16
Trx 9.8 5.7 — 30
GSSG — 1.6 210 [28] 21.7
HED — 1.2 — 17.8
ND, no activity detected.
doi:10.1371/journal.pmed.0040206.t002
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sealed modular incubator chamber (Billups-Rothenberg,
http://www.brincubator.com) ﬂushed with the same gaseous
mix. On day 2 of the experiment, 50 ll of fresh media was
added. Schistosomula were assessed daily for viability by
microscopy. For each time point at least 1,500 parasites were
scored as alive or dead in each experiment (three replicates of
500 each), and each experiment was repeated three times.
Total RNA was harvested from parasites after the course of
an experiment by TRI reagent, following the manufacturer’s
instructions (Sigma). Complementary DNA was synthesized
using 1 lg of RNA, 1 ll of oligo dT (500 lg/ml), and 1 llo f1 0
mM dNTP mix in a 10 ll reaction. The mixture was heated to
65 8C for 5 min and quickly chilled on ice. Then 4 ll of ﬁrst-
strand buffer, 2 ll of 0.1 M dithiothreitol, and 1 llo f
RNaseOut (Promega, http://www.promega.com) were added to
the mixture. The mix was incubated for 2 min and then 1 llo f
Thermoscript reverse transcriptase (200 U) (Invitrogen) was
added and incubated for 50 min at 42 8C. The reaction was
heated at 70 8C for 15 min to inactivate the enzyme. The
resulting single-stranded cDNAs were used as templates in
PCR reactions using gene-speciﬁc primers to amplify TGR
(forward 59-CTATTTCCGTAGACGTCTGT-39 and reverse
59-AATACAGTTTCCTTCCCGTT-39) or GAPDH (forward
59-GTTTTGGTCGTATCGGGAGA-39 and reverse
59-ATGCGTTAGAAACCACGGAC-39).
Cytotoxicity Assay
Cytotoxicity assays were performed using sulforhodamine
B to determine cellular protein content as described [25].
Brieﬂy, myeloma cell line SP2/0 was cultured in 96-well
microtiter plates containing 0.2 ml of RPMI-1640 per well at a
cell density of 1,000 per well at 37 8Ci n5 %C O 2. Cells were
treated with drug concentrations (or drug carrier alone) and
exposure times as indicated. After treatment, cells were ﬁxed
with 10% TCA at 4 8C for 1 h. Fixed cells were rinsed to
remove ﬁxative and then stained in 0.4% (w/v) sulforhod-
amine B (Sigma) in 1% acetic acid for 30 min. After washing
with 1% acetic acid and dye extraction in 10 mM Tris (pH
10.5), plates were read at A564nm. The A564nm of drug-treated
cells was compared to carrier-only-treated cells. The treat-
ments were done in triplicate and the experiments repeated
three times.
Table 3. Primary Screen of NADPH-Dependent Oxidoreductase Flavoprotein Inhibitors and Antischistosome Drugs as Inhibitors of S.
mansoni TGR
Chemical
Series
Reference Compound
a Activity of Enzyme
(% of Uninhibited Enzyme)
4H-pyrazino[2,1-a]isoquinolin-4-one [42] Praziquantel 100
3H-1,2-dithiole-3-thione [42] OPZ 13
Antimonate [30] PAT 0
Gold complexes [29,30] AF 0
Aurothioglucose 0
Aurothiomalate 0
Cis-platinum complexes [31] RMA19 20
RMA35 2
Mannich bases [33] CDE16–2 2
CDE4 1
3-DAP 0
1,4-Naphthoquinones [36–39] LS766 76
LS852 74
LS1121 71
LS908 70
LS1108 59
LS1114 56
LS1105 37
M5 37
JD155 30
LS808 26
Menadione 18
Plumbagin 15
LS826 5
JD159 0
Naphthazarin 0
Tricyclic aromatics [40,41] Methylene blue 100
1.2d 80
1.2f 78
Safranin 75
1.2c 73
1.3a 54
Assays were conducted at 25 8C in 200 ll in 96-well plates with 50 lM inhibitor, 100 lM NADPH, and 5 nM TGR in 0.1 M potassium phosphate (pH 7.4), 10 mM EDTA with a preincubation
step of 15 min. Upon addition of another aliquot of NADPH (final NADPH concentration of 100–200 lM) and 3 mM DTNB, the activity was measured during the first 3 min in by monitoring
the increase in A412 and comparing to controls without addition of inhibitor. The assays were done in triplicate.
aFor nomenclature and chemical names, see the cited references.
doi:10.1371/journal.pmed.0040206.t003
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The signiﬁcance of the reduction in worm burdens after AF
treatment was determined by two-tailed Student t-test.
Results
Biochemical and Kinetic Analysis of Recombinant S.
mansoni TGR
Because it is a selenoprotein, it is not possible to directly
express recombinant schistosome TGR in Escherichia coli.
However, after we added a bacterial-type selenocysteine
insertion sequence element to the open reading frame we
successfully expressed TGR, using the strategy previously
employed for production of mammalian TrxR [14,15]. The
puriﬁed recombinant TGR demonstrated substantial activity
with a broad range of substrates, combining the characteristic
activities of mammalian TrxR, GR, and Grx. The speciﬁc
activities were 10.2 U/mg with DTNB, 2.2 U/mg with Trx
(coupled to insulin reduction), 7.2 U/mg with GSSG, and 9.9
U/mg in a Grx assay coupled to HED. In addition, TGR could
also reduce sodium selenite, H2O2, tert-butyl hydroperoxide,
alloxan, lipoic acid, and lipoamide. It could not, however,
reduce dehydroascorbic acid or ubiquinone. Table 1 summa-
rizes the kinetic parameters of the enzyme with these
different substrates.
The enzymatic properties of recombinant parasite TGR
differed from those of mammalian TGR [26]; schistosome
TGR had greater GSSG reduction activity relative to Trx
reduction (GSSG:Trx ratio of 4:1), whereas native mouse TGR
had the reverse proportions (1:2), and S. mansoni TGR had 6-
fold higher Grx activity than mouse TGR (Table 2). The
activity and kinetic constants of recombinant S. mansoni TGR
were similar to those reported for mammalian TrxR [26] and
for human GR (Table 2) [27,28], although its activity was lower
than that of human GR.
Inhibition Studies on Recombinant S. mansoni TGR
In order to assess the potential for inhibition of TGR we
screened several structurally diverse series of compounds
(Figure S1) known to act as inhibitors of disulﬁde reductases
from various organisms. Screening was performed with a
TGR assay using DTNB, including a 15 min preincubation of
recombinant enzyme, inhibitor, and NADPH before addition
of substrate (Table 3). Compounds exhibiting .85% inhib-
ition in the initial screen were analyzed further to determine
IC50 values for GR, TrxR, and Grx activities of TGR using the
appropriate assays with a 15 min preincubation (Table 4). In
order to determine if compounds showed selective inhibition
of TGR compared to human TrxR and GR, the IC50 values for
TGR were compared to those of human TrxR and GR either
reported in literature or determined here (Table 4).
The gold complexes AF, aurothioglucose, and aurothioma-
late, which are efﬁcient inhibitors (i.e., with low Ki/IC50
values) of mammalian TrxR [29,30], were found also to be
efﬁcient TGR inhibitors. AF was the most potent inhibitor of
TGR, with IC50 values in the low nanomolar range.
Aurothioglucose had a less inhibitory effect on the reduction
of GSSG and Grx activity (HED-coupled assay) than on the
reduction of DTNB, whereas the other two gold compounds
inhibited to a similar extent all three principal activities of
TGR (Table 4). This indicates that the Grx activity, presum-
ably catalyzed by the N-terminal Grx domain of the enzyme
[11], could be dissociated from the other activities of the
enzyme, which should be catalyzed by the C-terminal GCUG
motif. This interpretation is corroborated by the fact that a
C-terminally His-tagged form of the enzyme lacking the Sec
residue was previously found to lack TrxR or GR activity,
while still supporting Grx activity [8].
Platinum drugs (e.g., RMA19 and RMA35) are also
irreversible inhibitors of mammalian TrxR [31,32]. RMA35,
but not RMA19, was here a potent inhibitor of TGR; it had
the opposite effect with human TrxR [31], indicating that
Table 4. IC50 Values of TGR Inhibitors with 15-Minute Preincubation Assays
Compound S. mansoni TGR Human GR Human TrxR
DTNB GSSG HED GSSG DTNB/Trx
AF 0.007 0.009 0.006 40 [29] 0.02 [29,30]
Aurothioglucose 0.07 3 0.4 .100 [29] 0.065 [29,30]
Aurothiomalate 0.09 0.05 0.05 ND 0.28 [30]
RMA35 4 6 ND 2.6 [31] 0.10 [31]
OPZ 80 50 ND 0%
a 37%
a
PAT 0.051 0.037 ND ND ND
3-DAP 0.5 7 ND ND ND
CDE4 7 0.5 ND .1 mM [33] 18.4
b,1 . 1
c
CDE16–2 25 1 ND ND ND
Naphthazarin 2.5 10 10 20
d 0.65 [36]
JD159 0.5 1 ND 4.5
d 0.08 [36]
LS826 8 8 ND NI at 25 lM [37] NI at 50 lM [37]
Compounds that inhibited enzyme activity .85% in the initial screen were analyzed further to determine IC50 values (lM) against TGR using the assays described in Table 3, including a 15
min preincubation step of TGR plus inhibitor and 100 lM NADPH. Assays using DTNB (3 mM), GSSG (100 lM), or HED (8 mM) plus GSH (1 mM) were used to determine TrxR, GR, and Grx
activities of TGR, respectively. Human enzymes were prepared as described [29]. Human TrxR activity was assayed with either Trx or DTNB as indicated in the cited references. The assays
were done in triplicate.
aThe percent inhibition was evaluated at 12.5 lM compound in the presence of 200 lM disulfide substrate and a preincubation period of 60 min at 37 8C.
bIn the presence of 3 mM DTNB and a preincubation period of 5 min at 25 8C.
cIn the presence of 21 lM Trx and a preincubation period of 5 min at 25 8C.
dIn the presence of 50 lM GSSG under steady state conditions.
ND, not determined; NI, no inhibition.
doi:10.1371/journal.pmed.0040206.t004
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selective TGR inhibitors.
The most active Mannich base, inhibitors of plasmodial and
kinetoplastid ﬂavoenzymes [33,34], was 3-DAP, with low
micromolar IC50 values against TGR. The naphthoquinones
juglone [35] and naphthazarin [36] and several of their
derivatives are subversive substrates of human TrxR. Among
the naphthoquinones, LS826 [37] behaved as a selective TGR
inhibitor, with an IC50 of 8 lM, but as a poor inhibitor of the
human enzymes. While the GR inhibitor M5 [38,39] had no
effect on TGR, naphthazarin and its derivatives JD155 and
JD159 [36] inhibited TGR, but not selectively. Tricyclic
aromatics,whichareinhibitorsofPlasmodiumfalciparumgrowth
and human GR [40,41], were inactive as inhibitors of TGR.
Similar to the interactions of mammalian TrxR with several
quinones [35], inhibitory compounds may function as both
substrates and inhibitors (i.e., subversive substrates) of TGR.
The interaction of schistosome TGR with naphthazarin was
found to exhibit this type of effect, with naphthazarin both
acting as substrate (Figure 2A) and leading to time-dependent
inhibition (Figure 2B and 2C).
We examined three antischistosomal drugs [42,43], prazi-
quantel, OPZ, and PAT. Both PAT and OPZ were here
efﬁcient, noncompetitive inhibitors of TGR (Figure 3); the Ki
values (6 standard deviation) for PAT were 4.86 6 0.46 nM
(TrxR activity) or 7.22 6 4.96 nM (GR activity), and for OPZ
were 18.1 6 1.1 lM (TrxR activity) or 33.8 6 6.0 lM (GR
activity). The widely used antischistosomal drug praziquantel
displayed no inhibitory activity against TGR.
Inactivation of S. mansoni TGR by OPZ followed pseudo-
ﬁrst order reaction kinetics. A semi-logarithmic plot of the
fraction of noninhibited enzyme activity ln(vi/v0)v e r s u s
incubation time yielded linear curves with increasing slopes,
equivalent to the apparent rate constant of irreversible
inhibition (kobs) in GR (Figure 4A) and in TrxR (Figure 4C)
assays. The kobs values determined for S. mansoni TGR
inactivation by OPZ ranged from 16.3 3 10
 3 min
 1 to 355.5
3 10
 3 min
 1 for GR activity and from 11.0 3 10
 3 min
 1 to
58.9 3 10
 3 min
 1 for TrxR activity, within the log-linear
range of the inhibition curve. When the derivation described
by Kitz and Wilson [44] for irreversible inactivation was
applied to the experimental data, only at low inhibitor
concentration, the secondary plot expressing kobs as a
function of inhibitor concentration followed Equation 2:
kobs ¼
ki½I 
KI þ½ I 
ð2Þ
where KI represents the dissociation constant of the
inhibitor, and ki is the ﬁrst-order rate constant for irrever-
sible inactivation. In both secondary plots (Figure 4B and 4D)
showing inactivation of S. mansoni TGR at low OPZ
concentrations, a rough estimation of ki, the resulting half-
time value (t1/2), and KI, were 0.04 min
 1, 17.3 min, and 32.8
lM in the GR assay, and 0.06 min
 1, 11.5 min, 140 lM in the
TrxR assay, respectively. The resulting second-order rate
constant values of ki/KI were 7.1 M
 1 s
 1 and 20.3 M
 1 s
 1 for
inactivation of, respectively, GR and TrxR activities by OPZ.
At higher inhibitor concentrations, the curves were not
hyperbolic, but became polynomial, suggesting that more
than one binding site of OPZ is involved in the presence of
reacted and unreacted enzymes species in mixture. A double
reciprocal replot of kobs versus [I] did not ﬁt to a linear
relationship (unpublished data). In close accord with ob-
servations made in recent studies on the inactivation of
human glutathione reductase [45] or of human thioredoxin
reductase [31], the inactivation of S. mansoni TGR by OPZ
likely involves distinct enzyme populations, i.e., the enzyme
species reduced at the ﬂavin for inhibitor reduction, or the
major two-electron reduced form with a dithiol in the active
site(s) for alkylation. Although covalent inactivation of the
enzyme was observed in both GR and TrxR assays, the kinetics
of inactivation indicated that OPZ interacts in a complex way
with the multifunctional enzyme S. mansoni TGR.
Inhibitor Studies on Cultured Worms
Because of the potent effect of AF on recombinant S.
mansoni TGR activity, we also analyzed its effect on worm
pairing (female worms are present in copula in the male
Figure 2. Naphthazarin Is a Substrate and Inhibitor of TGR
(A) Activity of recombinant S. mansoni TGR with naphthazarin as a
substrate was determined by NADPH consumption under steady-state
conditions.
(B) Time-dependent inhibition of TrxR activity of TGR by naphthazarin
with DTNB as a substrate. Concentrations of naphthazarin are 0.5 lM( ¤),
1 lM( n), 2.5 lM( m), 5 lM( 3), and 10 lM( þ).
(C) Time-dependent inhibition of TGR activity with GSSG. Concentrations
of naphthazarin are 0.5 lM( ¤), 1 lM( n), 2.5 lM( m), 5 lM( 3), and 10 lM
(þ).
doi:10.1371/journal.pmed.0040206.g002
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days in optimal axenic culture) and worm viability (as
evidenced by muscle contraction and parasite movement).
Incubating worms with 10 lM AF resulted in unpairing of
male and female worms after 1 h, 83% mortality after 6 h, and
100% mortality after 9 h of treatment; control worms
remained paired and active throughout the treatment. When
compared to control worms, TrxR and GR activities of TGR
in worm homogenates were nearly 100% inhibited after 1 h
of treatment with 10 lM AF (Figure 5A). In contrast, the
activities of control enzymes, LDH and GPx, showed no
signiﬁcant deviation from controls (Figure 5A). The ratio of
GSH:GSSG was also determined at each time point. The
control worms displayed a relatively constant ratio of ;18:1,
while in AF-treated worms a gradual oxidation of glutathione
was detected as early as 1 h of AF treatment. After 6 h of
treatment the GSH:GSSG ratio had decreased by 85% to 2.6:1
(Figure 5B).
Likewise, larval, skin stage parasites, and juvenile liver stage
parasites (unpublished data) are killed in less than 10 h by AF
at concentrations as low as 5 lM (Figure 6A). For comparison,
a mammalian cell line tolerated AF at concentration as high
as 100 lM for 5 d, while 5 lM AF led to adult worm death in
24 h (Figure 6B). A similarly large differential in toxicity
between adult worms and mammalian cells for PAT was also
found (Figure 6C).
In Vivo Inhibition Studies
To further investigate the potential of TGR as a drug
target, we analyzed the possible effects of AF treatment on
the survival of worms in mammalian hosts. In preliminary
studies, mice infected with S. mansoni were administered 6 mg/
kg AF twice daily for 9 d, which is a safe dose for healthy mice
[46], beginning 7 wk after infection (when adult worms are
present in the mesenteric venules) followed by a 1 wk rest.
Mice were then perfused and worms were collected and
counted. In two independent experiments utilizing different
mouse strains, the AF-treated mice had a 59% and 63%
decreases in worm burden compared to control mice (Table
5).
RNAi Silencing of TGR
In order to further analyze the importance of TGR for
worm survival, we incubated schistosomula (larval parasites)
with double-stranded TGR RNA to silence TGR expression.
After 2 d of TGR dsRNA treatment, TGR activity (using
DTNB as substrate) was reduced by 35% in parasites in
aerobic culture (20% O2) and after 3 d of TGR dsRNA
treatment, TGR activity was reduced by 61% or 63.5% in
parasites cultured anaerobically or aerobically, respectively.
A marked decrease in TGR mRNA after 3 d of treatment was
also seen (Figure 7A). The RNAi silencing of TGR led to
substantial decreases in parasite survival; approximately 92%
of dsRNA-treated parasites were dead after 4 d of treatment
both in aerobic and anaerobic conditions (Figure 7B).
Control parasite survival was over 95% in both aerobic and
anaerobic growth conditions. After 3 d, TGR dsRNA-treated
parasites had darker bodies with internal vacuoles and did
not move, while all irrelevant dsRNA-treated parasites
showed contractile movement and had clear bodies (Figures
8 and S2). Treatment of cultured parasites with sublethal
levels of AF and TGR dsRNA showed an additive effect
Figure 3. Inhibition of S. mansoni TGR by PAT and OPZ
Reciprocal plots showing inhibition of the TrxR and GR activities of TGR by PAT (A) and OPZ (B). Both are noncompetitive inhibitors, altering the Vmax
while the Km for substrates remains constant. The apparent Vmax for various concentrations of inhibitors were used to calculate Ki values. Concentrations
of PAT are no drug (¤), 10 nM (&), 30 nM (m), and 75 nM (3); and of OPZ are no drug (¤), 50 lM( &), 75 lM( m), and 100 lM( 3). Concentrations of DTNB
ranged from 50 to 1,000 lM (TrxR activity) and of GSSG from 10 to 100 lM (GR activity).
doi:10.1371/journal.pmed.0040206.g003
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pared to RNAi or AF treatments alone (Figure 7C).
Schistosomula treated with both TGR dsRNA and 2 lMA F
had 49.8% 6 2.8 % survival after 1 d compared to 91.3% 6
1.1% for RNAi alone and 93.7% 6 1.1% for 2 lM AF alone (p
, 0.001), and after 2 d survival in the combination treatment
was 8.9% 6 1.5% compared to 66.1% 6 1.4% for 2 lMA F
alone and 76.1% 6 3.2% for RNAi alone (p , 0.001), with
similarly signiﬁcant results over the remainder of the 4 d time
course. Praziquantel had no effect alone or in combination
with RNAi.
Discussion
In this study we have demonstrated that TGR is an essential
protein for the survival of S. mansoni and that it meets all the
major criteria of an important target for antischistosomal
chemotherapy development. Silencing of TGR expression by
RNAi lead to rapid parasite death, and auranoﬁn, a speciﬁc
chemical inhibitor of TGR, provides partial parasitological
cures of infected mice. We have screened a number of TGR
inhibitors and identiﬁed potential lead compounds for novel
drug development. Furthermore, we demonstrated that TGR
was likely a key target of some earlier therapies.
It has been suggested that antioxidants play an important
role in protecting adult S. mansoni worms from immune attack
by the host [47]. Recent studies indicate that the enzymatic
antioxidant pathway in S. mansoni is uniquely dependent on
TGR [11]. In the parasite, TGR completely replaces more
specialized TrxR and GR orthologs and, therefore, TGR
functions in reducing both Trx and GSSG. This may lead to a
bottleneck effect that should make TGR an attractive drug
target. The results presented here strengthen this hypothesis.
Recombinant S. mansoni TGR was here shown to possess
substantial TrxR, GR, and Grx activity, with rates comparable
to those reported for native TGR puriﬁed from mouse testis
[26] and more than 40-fold more active than recombinant
mouse TGR [48]. When S. mansoni TGR was ﬁrst cloned, we
proposed that the enzyme was a selenoprotein with a
penultimate Sec residue, and that TGR should have enzymatic
activity dependent on the C-terminal Sec-containing motif in
analogy to mammalian TrxR and TGR isoforms [11]. This
study, in which the enzyme was expressed as a selenoprotein,
Figure 4. Time-Dependent Inactivation of S. mansoni TGR by OPZ
The time dependency of inactivation of S. mansoni TGR (15 pmol/ll) was revealed by determining the residual GR (A) and TrxR (C) activities of enzyme
in the presence of 100 lM NADPH and inhibitor at 0, 2, 4, 10, and 30 min incubation periods. OPZ concentrations were 0 ( ), 25 (&), 50 (¤), 75 (D), and
100 (m) lM. All incubation mixtures included 2% final DMSO. The kobs data as a function of inhibitor concentration from the GR (B) or TrxR assay (D)
versus OPZ concentrations followed a polynomial equation (not shown), suggesting that more than one binding site of OPZ is involved in the presence
of different enzyme species of reacted and unreacted enzymes in mixture during the course of the inactivation process. The error bars in (B) and (D)
represent 6 the standard errors of the kobs values estimated separately at each inhibitor concentration, as obtained from nonlinear regression analysis.
doi:10.1371/journal.pmed.0040206.g004
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however, that the Grx activity of the enzyme was sustained
without the C-terminal motif, as shown here and previously
[11].
Characterization of the parasite TGR revealed enzymatic
properties that differed from those of mammalian TGR,
TrxR, and GR. TGR was also identiﬁed as a multifunctional
oxidoreductase with a remarkably wide substrate speciﬁcity,
capable of directly reducing peroxides, selenium-containing
compounds, and several important low-molecular-weight
antioxidants, as well as Trx, DTNB, GSSG, and GSH-HED.
However, TGR was unable to reduce dehydroascorbic acid or
ubiquinone, compounds that are reduced by mammalian
TrxR1 [49,50]. These ﬁndings show that TGR is likely to serve
multiple functions in the parasite and is functionally distinct
from the TrxR and GR orthologs of the human host. These
substrate preferences might possibly be exploited for future
TGR-directed anti-schistosome drug design.
Several additional differences exist between schistosome
TGR and mammalian TGR, TrxR1, TrxR2, or GR. In
mammals, TGR is thought to serve a highly specialized
function with expression restricted primarily to the testis
[26,51]. Both TrxR1 and TrxR2 isoenzymes have a nearly
ubiquitous distribution in mammalian tissues; TrxR1 is
predominantly a cytoplasmic enzyme [52], while TrxR2 is
mitochondrial [53]. GR is also widely distributed and is
believed to be primarily cytoplasmic, although at least in
yeast an alternatively translated isoform is targeted to the
mitochondria [54]. For Schistosoma spp. it seems clear that
TGR accounts for the complete combined Trx and GSSG
reduction in the parasite. Moreover, schistosome TGR mRNA
is alternatively spliced, producing both cytoplasmic and
Figure 5. The Activity of Auranofin against Cultured Schistosoma mansoni
Each point is the average of three independent experiments 6 the standard deviation.
(A) Specific enzyme activities of TrxR, GR, LDH, and GPx in worm homogenates from control worms (solid lines) and worms treated with 10 lMA F
(dashed lines).
(B) Ratio of GSH:GSSG in worm homogenate from control worms (solid line) and worms treated with 10 lM AF (dashed line). Each assay was done in
triplicate and each experiment was done three times. The error bars show the standard deviation of the three replicate experiments.
doi:10.1371/journal.pmed.0040206.g005
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lished data). Therefore, it appears that schistosome TGR
fulﬁlls all of the major functions of the mammalian TGR,
TrxR1, TrxR2, and GR orthologs, emphasizing the impor-
tance of the parasite protein, and this alone should make it an
attractive target for treatment of schistosomiasis. Because
redox metabolism in other medically important parasitic
platyhelminths is thought to be similar to S. mansoni [55],
targeted inhibition of parasite TGR orthologs may also be a
useful strategy to develop drugs against other parasitic
infections.
The previously used antischistosome drugs PAT and OPZ
inhibited recombinant schistosome TGR, suggesting that the
enzyme may already have served as a target protein for
antischistosomal therapy. The dithiolethione compound OPZ
reached Phase III clinical trials for schistosomiasis treatment
[42] before it was withdrawn because of adverse side affects
[56].
Although the mechanism of action of OPZ is not well
deﬁned, it has been reported to decrease GSH levels in adult
S. mansoni worms [57]. Previous studies have shown that OPZ
requires metabolite bioactivation both to display potent
schistosomicidal activity and inhibition of the GSSG reduc-
tion activity [58]. The metabolism of OPZ in humans was
investigated and the structures of active metabolites were
identiﬁed (Figure 9). Metabolism of OPZ results in the
production of a minor oxo analog, and the major dimethy-
lated pyrrolopyrazine through the biological methylation of
the intermediate pyrrolopyrazine thione. Two general hy-
potheses have been proposed to explain the mechanisms of
OPZ activation [59]. The ﬁrst suggests that OPZ acts through
a bioactive metabolite following reaction with cellular thiols.
The generation of the major methylated pyrrolopyrazine
thione, an electrophilic intermediate species (structure 4,
Figure 9), would lead to alkylation of protein thiols. While the
disulﬁde bond of dithiolethiones is more difﬁcult to reduce
than a linear disulﬁde bond because of its aromatic character,
the same pyrrolopyrazines can be obtained both by chemical
(use of thiols like GSH) and electrochemical methods from
OPZ. The greater reactivity of dithiols compared to mono-
thiols with respect to reactions with dithiolethiones was
determined to be due to an intrinsic enhanced reactivity of
speciﬁc biological dithiol targets [60]. The second hypothesis
also involves redox reactions from the major methylated
pyrrolopyrazine thione (structure 4, Figure 9) in the presence
of oxygen, contributing to a ﬂux of reactive oxygen species
[61,62]. Some disulﬁde intermediates (structure 5, Figure 9)
displaying high schistosomicidal activity were shown to act as
prodrugs of the pyrrolopyrazine thione (structure 4, Figure 9)
[58].
The action mechanism of OPZ against S. mansoni was also
extensively investigated. The schistosomicidal activity of OPZ
was correlated with glutathione depletion and a 2-fold lower
GSSG reduction activity in S. mansoni, which was assigned to
the action of a metabolite (having the general structure 5,
Figure 9) rather than to OPZ itself [58]. Initially, GR was
proposed to be responsible for GSSG reduction activity in S.
mansoni and thus to be the target of OPZ. However, because
there is no classical GR in this parasite, we checked the
activity of OPZ as inhibitor of S. mansoni TGR and/or the
prodrug of the species involved in decreased S. mansoni TGR
activity in worms. Our results suggest that the antischistoso-
Figure 6. Survival of Schistosomula, Adult Worms, and Myeloma Cells in
the Presence of Auranofin or Potassium Antimonyl Tartrate
(A) Cultured schistosomula treated with 0 lM AF (dashed line); AF 0.5 lM
(¤); 1 lM (*); 2 lM (x); 5 lM( m); 10 lM( &).
(B) Survival of adult Schistosoma mansoni worms at 24 h (dashed line),
myeloma cells at 24 h (&); and myeloma cells at 5 d (¤) at given
concentrations of AF.
(C) As in (B) in the presence of given concentrations of PAT.
Each treatment was done in triplicate and each experiment was done
three times. Error bars show the standard deviation of the three replicate
experiments.
doi:10.1371/journal.pmed.0040206.g006
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inhibition of schistosome TGR and that OPZ should be
revisited to improve its toxicological proﬁle.
The ﬁrst chemotherapy used for schistosomiasis was PAT, a
trivalent antimonial that was administered to patients
infected with S. haematobium beginning in 1917 [63]. PAT
and other trivalent antimonials dominated chemotherapy for
schistosomiasis until the introduction of praziquantel in the
1980s. Earlier studies suggested that the antischistosome
action of trivalent antimonials is due to the selective
inhibition of the parasite glycolytic enzyme phosphofructo-
kinase (PFK) [64,65]. As found here, PAT is a noncompetitive
TGR inhibitor with a Ki value in the low nanomolar range,
showing that PAT is by three orders of magnitude a better
inhibitor of TGR than of PFK, which has an IC50 of 16 lM
[65]. Combined with our other results, this suggests that the
chemotherapeutic action of PAT is more likely to occur
through inhibition of parasite TGR and than of PFK, or that
inhibition of both enzymes provides a synergistic antipar-
asitic affect. We are currently carrying out investigations to
test this hypothesis.
Gold compounds may inhibit selenoproteins by targeting
the Sec residue, and mammalian TrxR is a selenoprotein that
is especially sensitive to such inhibition [29]. Auranoﬁn,
aurothiomalate, and aurothioglucose have all been used
clinically for the treatment of rheumatoid arthritis [66]. Here
we found that gold compounds are also potent inhibitors of
schistosome TGR. It should also be noted that, although
schistosomes express a GPx with a catalytically active Sec
residue [67], GPx activity was not inhibited by AF (Figure 5).
Furthermore, the inhibition of TGR by AF in cultured worms
greatly reduced the GSH:GSSG ratio and resulted in rapid
worm death. These results on cultured worms support the
conclusion that TGR should be a prime target for anti-
schistosomal drug therapy. The signiﬁcant decrease in worm
burden in infected mice treated with AF also supports this
notion. The concentration of AF used to achieve this affect
was well tolerated by the mice in this and previous studies
[46], and it was reported previously that mammalian cells
have over 95% viability when cultured in 10 lM AF [68]. The
reasons for a generally low toxicity toward mammalian cells
by AF are not known but could involve low uptake or efﬁcient
metabolic defense systems. While mammalian cells and the
infected mouse hosts obviously tolerated the dosage of AF
used in our studies, the results presented here show that
larval, juvenile, and adult parasites are extremely sensitive to
killing by AF. It should be noted that the toxic effects of AF
occurred in the absence of exogenous oxidative stress (e.g., no
added H2O2 or other oxidant) on the worms.
Partial parasite clearance with AF is not an invalidation of
S. mansoni TGR as an essential protein; factors such as the low
in vivo bioavailability of AF might be the cause of the
incomplete worm clearance. It is also important to emphasize
that although the development of a schistosomiasis drug
leading to partial cures is not a preferred goal, there are a
number of factors associated with schistosome infections to
consider. For example, unlike bacterial or protozoal infec-
tions, which require 100% cure rates or risk relapse,
reduction of worm burdens by 50% would lead to signiﬁcant
decreases in pathology and morbidity associated with
schistosomiasis, and no rebound in pathology would occur
because adult worms do not multiply in their host.
Furthermore, because praziquantel is highly effective and
has low toxicity, it is essential to identify new drugs that can
be used in combination with it to prevent parasites from
developing resistance. Combination therapies may be useful
to prevent praziquantel resistance even if only partial worm
reductions were affected by the new drug alone. The
effectiveness of artemisinin derivatives in combination
therapy with praziquantel against schistosomiasis has been
demonstrated [3], but concerns remain that the use of
artemisinins for multidrug-resistant malaria treatment not
be compromised. Our results indicate that praziquantel does
not inhibit TGR; therefore, it is reasonable to assume that
drugs targeting TGR will have a different mechanism of
action than praziquantel. Unlike the more selective action of
praziquantel against larval and adult parasites [69,70] and
artemisinin against juvenile parasites [71], respectively,
inhibition of TGR led to both larval and adult parasite death.
Development of drugs targeting parasite TGR may thus
provide the opportunity for prophylactic therapies. We
propose that the screen for inhibitors of TGR as initiated
here be continued and that it may lead to the development of
novel drugs with potent antischistosomal effects. In this
context it should be noted that the kinetics of inhibition of
TGR may be rather complex, as discussed above for OPZ.
Further studies are therefore needed with the different
inhibitors already identiﬁed in the present study for a
characterization of their interactions with TGR.
With TGR being a probable important drug target for
treatment of schistosomiasis, is it an essential protein for the
parasite? The RNAi treatments silencing TGR expression that
led to signiﬁcant decreases in parasite survival indicate that it
is. The TGR dsRNA treatment led to a signiﬁcant decrease in
Table 5. Effect of AF Treatment in Mice Experimentally Infected with S. mansoni
Mouse
Strain
Treatment Animals, n Total Worm Burden, Number
of Worms, Mean 6 SD
Total Worm Burden
Reduction, %
C57BL/6 Control 7 29 6 13.7 59
a
AF 8 12 6 7.8
NIH-Swiss Control 7 23 6 2.2 63
b
AF 7 8.6 6 1.7
Treatment: 6 mg/kg twice daily for 9 d.
aFor C57BL/6 mice receiving auranofin treatment versus the controls, p , 0.015 by t test.
bFor NIH-Swiss mice receiving auranofin treatment versus the controls, p , 0.001 by t test.
doi:10.1371/journal.pmed.0040206.t005
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with irrelevant dsRNA had no effect. Genome sequence
analysis, although not complete, represents ;95% coverage
of the S. mansoni genome. Analysis of the genome sequence
indicates that TGR is a single-copy gene (unpublished data)
and no other activity is present in worms for Trx and GSH
reduction [11]. Parasite death, which occurred in either
aerobic or anaerobic conditions, was presumably due to
pleiotropic effects of silencing TGR. Furthermore, combined
treatment of schistosomula with TGR dsRNA and AF showed
signiﬁcant synergistic effects, suggesting that both act by
decreasing TGR activity. Identiﬁcation of the exact mecha-
nism for the lethal effect of silencing the enzyme requires
further experiments, as do the effects of inhibitors, which are
not necessarily solely due to loss of enzyme activity, because
the inhibited enzyme may also have a gain of function leading
to cell death [72].
To conclude, in this report we have provided the ﬁrst, to
our knowledge, comprehensive biochemical analysis of a TGR
selenoprotein from any organism, showing that it has
remarkably wide substrate speciﬁcity and may be effectively
inhibited by a number of low-molecular-weight compounds.
Furthermore, using both inhibitors and RNA silencing we
have shown that TGR is an essential schistosome protein, and
we believe that our results have validated it as a key drug
target for treatment of schistosomiasis.
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Days of Treatment
Schistosomula treated with irrelevant dsRNA are shown in the image
on the left; those treated with TGR dsRNA are on the right. All
organisms in the left image are alive; parasites have different shapes,
elongated, contracted, and curved during movement. In the right
image, all of the parasites are dead and have roughly the same shape
(no movement) and internal vacuoles (arrows). The bar represents
330 lm.
Found at doi:10.1371/journal.pmed.0040206.sg002 (7.5 MB EPS).
Figure 8. Photomicrographs (1003) of Irrelevant dsRNA-Treated
Schistosomula (left image) and TGR dsRNA-Treated Schistosomula (right
image) after Three Days of Treatment
All organisms in the left image are alive; parasites have different shapes,
elongated, contracted, and curved during movement. In the right image,
all of the parasites are dead and have roughly the same shape (no
movement) and internal vacuoles (arrows). The bar represents 250 lm.
doi:10.1371/journal.pmed.0040206.g008
Figure 7. Survival of Schistosomula after RNAi Silencing of TGR
Expression
(A) Qualitative measure of TGR transcripts by reverse transcription PCR.
The abundance of TGR mRNA was greatly reduced by dsRNA treatment
while the control gene GAPDH was unaffected.
(B) Parasites were cultured in the presence of double-stranded TGR RNA
(dashed lines) or of double-stranded irrelevant RNA (solid lines) in 20%
O2 (¤)o r0 %O 2 (&). A 500-nucleotide fragment (bp 1364–1866) of S.
mansoni TGR cloned into PCRII-TOPO vector was used to transcribe TGR
dsRNA. Irrelevant, nonschistosome dsRNA used for negative controls was
synthesized from the PCRII-TOPO vector using T7 and SP6 RNA
polymerases.
(C) Combination of RNAi and drug treatments. Solid lines are irrelevant
dsRNA treatments and dashed lines are dsTGR treatments; no additions
(¤), 2 lM praziquantel (&) and 2 lMA F( m). At each time point, data
comparing the combination treatment (2 lMA FþTGR dsRNA) to either
2 lM AF or TGR dsRNA alone were statistically significant (*p , 0.004). In
each experiment for each time point at least 1,500 parasites were scored
as alive or dead (three replicates of 500 parasites). The error bars
represent the standard deviations of three independent experiments.
doi:10.1371/journal.pmed.0040206.g007
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Background. More than 200 million people are infected with
schistosomes, a type of parasitic worm. Schistosomes have a complex
life cycle that starts with them reproducing in freshwater snails. The
snails release free-swimming, infectious parasites that burrow into the
skin of people who swim in the contaminated water. Once in the human
host, the parasites turn into larvae and migrate to the liver where they
become juvenile worms. These mature into 10- to 20-mm-long adult
worms and take up long-term residence in the veins draining the gut
(Schistosoma mansoni and S. japonicum) or bladder (S. haematobium).
Here, the worms mate and release eggs, some of which pass into the
feces and so back into water where they hatch and infect fresh snails.
Schistosomiasis causes serious health problems (including chronic liver,
gut, bladder, and spleen damage) in about 20 million people, making it a
disease of great public-health and socioeconomic importance in the
developing countries in which it mainly occurs.
Why Was This Study Done? The only drug available to treat
schistosomiasis is praziquantel. Although it is very effective, people
regularly get reinfected and need to be retreated once or twice a year. All
told, 100 million people are currently being treated with praziquantel.
Reliance on a single drug, however, is problematic, as the parasites are
likely to develop resistance to the drug over time. The identification of
new drug targets in schistosomes is therefore an urgent goal. In this
study, the researchers have investigated whether thioredoxin gluta-
thione reductase (TGR), a parasitic enzyme with several functions, might
be a key target for antischistosomal chemotherapy. They chose this
enzyme because adult worms need to make antioxidants (chemicals that
prevent oxygen from damaging cells) to protect themselves against the
human immune response. Antioxidant production in these worms
depends on TGR; in mammalian cells, two specialized enzymes do its job.
The researchers reasoned, therefore, that TGR might be an essential
parasite protein and a potentially important drug target.
What Did the Researchers Do and Find? The researchers made large
quantities of pure TGR and tested its activity against various substrates.
The enzymatic properties and substrate preferences of TGR, they found,
differed somewhat from those of its mammalian counterparts. They then
screened different types of compounds for their ability to inhibit TGR.
Praziquantel had no effect on TGR activity, but two antischistosomal
compounds that are no longer used, potassium antimonyl tartrate and
oltipraz, inhibited the enzyme. The most potent inhibitor of TGR,
however, was a gold-containing complex called auranofin, low levels of
which inhibited TGR in test tubes, completely killed larval, juvenile, and
adult parasites living in laboratory dishes within hours, and more than
halved the worm burden in infected mice. Finally, the researchers used a
technique called RNA silencing to test the importance of TGR for worm
survival. Fragments of double-stranded RNA (dsRNA) stop proteins being
made from messenger RNA that contains an identical sequence. The
addition of TGR dsRNA to larval parasites in a dish greatly reduced TGR
enzyme activity and killed nearly all the parasites within days.
What Do These Findings Mean? These findings suggest TGR as a key
target for antischistosomal drug development. Indeed, the discovery that
two previously used antischistosomal compounds inhibit TGR suggests
that the enzyme has already served as a target protein. The RNA
silencing experiment shows that TGR is essential for parasite survival, and
the biochemical analyses indicate that TGR and its mammalian counter-
parts have different substrate specificities. Thus, it should be possible to
find compounds that inhibit TGR but have much less effect on the
mammalian enzymes. This is certainly true for auranofin, a drug used to
treat rheumatoid arthritis. Whether auranofin will be an effective
treatment for schistosomiasis remains to be seen—an agent that
completely kills schistosomes in animals would be preferable. However,
even a 50% reduction in worm burden would decrease the human
health problems caused by schistosomiasis, and a combination of
auranofin (or another TGR inhibitor) with an agent that works by a
different mechanism might be more effective and would also reduce the
chances of the parasite developing drug resistance.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040206.
  World Health Organization provides information on schistosomiasis,
including a fact sheet in English, Spanish, French, Arabic, Chinese, and
Russian
  US Centers for Disease Control and Prevention provide information for
the public and for professionals on schistosomiasis
  MedlinePlus encyclopedia includes an entry on schistosomiasis (in
English and Spanish)
  The Schistosomiasis Control Initiative has information on the disease
and its control
  Wikipedia has a page on schistosomiasis that is available in several
languages (note: Wikipedia is a free online encyclopedia that anyone
can edit)
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